Biomea Fusion (BMEA) Competitors $2.50 -0.03 (-1.19%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$2.50 0.00 (0.00%) As of 04:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BMEA vs. CKPT, RZLT, VIGL, SLDB, CMPX, ADCT, AQST, SNDL, CYRX, and IVAShould you be buying Biomea Fusion stock or one of its competitors? The main competitors of Biomea Fusion include Checkpoint Therapeutics (CKPT), Rezolute (RZLT), Vigil Neuroscience (VIGL), Solid Biosciences (SLDB), Compass Therapeutics (CMPX), ADC Therapeutics (ADCT), Aquestive Therapeutics (AQST), SNDL (SNDL), Cryoport (CYRX), and Inventiva (IVA). These companies are all part of the "pharmaceutical products" industry. Biomea Fusion vs. Its Competitors Checkpoint Therapeutics Rezolute Vigil Neuroscience Solid Biosciences Compass Therapeutics ADC Therapeutics Aquestive Therapeutics SNDL Cryoport Inventiva Biomea Fusion (NASDAQ:BMEA) and Checkpoint Therapeutics (NASDAQ:CKPT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, community ranking, valuation, dividends and risk. Do institutionals & insiders believe in BMEA or CKPT? 96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 22.0% of Checkpoint Therapeutics shares are held by institutional investors. 18.4% of Biomea Fusion shares are held by insiders. Comparatively, 2.1% of Checkpoint Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more volatility and risk, BMEA or CKPT? Biomea Fusion has a beta of -0.23, suggesting that its share price is 123% less volatile than the S&P 500. Comparatively, Checkpoint Therapeutics has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Does the media favor BMEA or CKPT? In the previous week, Biomea Fusion had 1 more articles in the media than Checkpoint Therapeutics. MarketBeat recorded 2 mentions for Biomea Fusion and 1 mentions for Checkpoint Therapeutics. Checkpoint Therapeutics' average media sentiment score of 1.87 beat Biomea Fusion's score of 1.10 indicating that Checkpoint Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Biomea Fusion Positive Checkpoint Therapeutics Very Positive Is BMEA or CKPT more profitable? Checkpoint Therapeutics' return on equity of 0.00% beat Biomea Fusion's return on equity.Company Net Margins Return on Equity Return on Assets Biomea FusionN/A -118.90% -93.66% Checkpoint Therapeutics N/A N/A -659.07% Which has preferable earnings and valuation, BMEA or CKPT? Checkpoint Therapeutics has higher revenue and earnings than Biomea Fusion. Checkpoint Therapeutics is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiomea FusionN/AN/A-$117.25M-$3.55-0.70Checkpoint Therapeutics$41K9,041.59-$51.85M-$1.29-3.30 Do analysts recommend BMEA or CKPT? Biomea Fusion currently has a consensus price target of $21.40, indicating a potential upside of 756.00%. Checkpoint Therapeutics has a consensus price target of $4.33, indicating a potential upside of 1.72%. Given Biomea Fusion's stronger consensus rating and higher possible upside, equities analysts clearly believe Biomea Fusion is more favorable than Checkpoint Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomea Fusion 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.18Checkpoint Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the MarketBeat Community believe in BMEA or CKPT? Checkpoint Therapeutics received 116 more outperform votes than Biomea Fusion when rated by MarketBeat users. However, 70.21% of users gave Biomea Fusion an outperform vote while only 67.16% of users gave Checkpoint Therapeutics an outperform vote. CompanyUnderperformOutperformBiomea FusionOutperform Votes6670.21% Underperform Votes2829.79% Checkpoint TherapeuticsOutperform Votes18267.16% Underperform Votes8932.84% SummaryBiomea Fusion beats Checkpoint Therapeutics on 10 of the 17 factors compared between the two stocks. Get Biomea Fusion News Delivered to You Automatically Sign up to receive the latest news and ratings for BMEA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BMEA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMEA vs. The Competition Export to ExcelMetricBiomea FusionPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$93.93M$6.85B$5.57B$8.63BDividend YieldN/A2.56%5.28%4.18%P/E Ratio-0.628.7827.1220.06Price / SalesN/A255.64412.30157.10Price / CashN/A65.8538.2534.64Price / Book0.536.557.064.70Net Income-$117.25M$143.93M$3.23B$247.88M7 Day Performance2.04%3.84%2.86%2.63%1 Month Performance41.24%11.20%9.07%6.36%1 Year Performance-46.00%4.18%31.45%14.05% Biomea Fusion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMEABiomea Fusion2.8403 of 5 stars$2.50-1.2%$21.40+756.0%-43.6%$93.93MN/A-0.6250Positive NewsCKPTCheckpoint Therapeutics2.5051 of 5 stars$4.26flat$4.33+1.7%N/A$370.71M$41K-2.3210RZLTRezolute2.7209 of 5 stars$4.31-2.7%$11.83+174.6%-18.5%$368.59MN/A-3.5340Positive NewsVIGLVigil Neuroscience4.0548 of 5 stars$7.88flat$10.80+37.1%+71.6%$367.78MN/A-3.8340Positive NewsHigh Trading VolumeSLDBSolid Biosciences3.7698 of 5 stars$4.62+1.8%$14.90+222.5%-38.6%$358.12M$8.09M-1.52100Analyst RevisionCMPXCompass Therapeutics3.7061 of 5 stars$2.57+2.8%$13.13+410.7%+99.2%$355.39M$850K-6.9520ADCTADC Therapeutics2.8592 of 5 stars$3.57-2.7%$7.75+117.1%+13.2%$354.07M$75.82M-1.49310Positive NewsAnalyst RevisionGap UpAQSTAquestive Therapeutics1.7742 of 5 stars$3.54-0.6%$10.14+186.5%+21.4%$351.62M$54.23M-7.87160Positive NewsAnalyst RevisionSNDLSNDL3.6089 of 5 stars$1.33+0.8%$3.63+172.6%-34.8%$349.49M$927.61M-4.29580News CoverageCYRXCryoport3.5131 of 5 stars$6.96-0.6%$11.00+58.0%-34.9%$348.95M$232.13M-2.061,020Positive NewsIVAInventiva2.1321 of 5 stars$3.63+0.4%$10.40+186.9%+8.3%$346.78M$9.20M0.00100News CoverageGap Down Related Companies and Tools Related Companies CKPT Alternatives RZLT Alternatives VIGL Alternatives SLDB Alternatives CMPX Alternatives ADCT Alternatives AQST Alternatives SNDL Alternatives CYRX Alternatives IVA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BMEA) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomea Fusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomea Fusion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BMEA Stock Free BMEA Stock Alerts